Capricor Therapeutics announces promising long-term results for deramiocel deramiocel in Duchenne muscular dystrophy
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company at the forefront of developing cell and exosome-based therapies, has shared encouraging three-year safety and efficacy results from ... Read More
Urovant Sciences acquires licensing for hMaxi-K gene therapy to treat overactive bladder from Ion Channel
Urovant Sciences has secured global licensing rights from Ion Channel Innovations for the development and commercialization of a promising gene therapy, hMaxi-K. This therapy is ... Read More